Bank of Montreal’s DiaMedica Therapeutics DMAC Stock Holding History

Bank of Montreal’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$387K	Buy	54,944 +36,309	+195%	+$223K	﹤0.01%	2616
2026 Q1	$126K	Buy	18,635 +3,075	+20%	+$24.4K	﹤0.01%	3071
2025 Q4	$124K	Hold	15,560	–	–	﹤0.01%	2988
2025 Q3	$107K	Hold	15,560	–	–	﹤0.01%	2951
2025 Q2	$60.7K	Hold	15,560	–	–	﹤0.01%	3105
2025 Q1	$59K	Hold	15,560	–	–	﹤0.01%	3037
2024 Q4	$84.5K	Buy	+15,560	New	+$73.4K	﹤0.01%	2990
2021 Q3	–	Sell	-142,846	Closed	-$694K	–	3832
2021 Q2	$694K	Buy	142,846 +38,322	+37%	+$314K	﹤0.01%	2668
2021 Q1	$982K	Buy	104,524 +22,642	+28%	+$212K	﹤0.01%	2209
2020 Q4	$764K	Buy	81,882 +81,572	+26,314%	+$446K	﹤0.01%	2437
2020 Q3	$1K	Hold	310	–	–	﹤0.01%	4688
2020 Q2	$2K	Hold	310	–	–	﹤0.01%	4515
2020 Q1	$1K	Hold	310	–	–	﹤0.01%	3947
2019 Q4	$2K	Hold	310	–	–	﹤0.01%	4773
2019 Q3	$1K	Hold	310	–	–	﹤0.01%	4670
2019 Q2	$2K	Hold	310	–	–	﹤0.01%	4752
2019 Q1	$1K	Buy	+310	New	+$1.12K	﹤0.01%	4199

Other funds holding DMAC

CLG

Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Bank of Montreal's DMAC Position: Q2 2026 in Review

Bank of Montreal increased its DiaMedica Therapeutics (DMAC) stake by 195% in Q2 2026, buying an estimated $223K and bringing the position to 54,944 shares worth $387K. The position accounts for ﹤0.01% of the portfolio, ranked #2616.

Bank of Montreal first reported a position in DMAC in Q1 2019 and has held it in 17 quarters since. The position peaked at $982K in Q1 2021. 70 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

Bank of Montreal held 54,944 shares of DiaMedica Therapeutics worth $387K as of Q2 2026.
Bank of Montreal bought 36,309 DiaMedica Therapeutics shares in Q2 2026, an estimated $223K.
DiaMedica Therapeutics made up ﹤0.01% of Bank of Montreal's portfolio in Q2 2026, its #2616 holding.
Bank of Montreal first reported a position in DiaMedica Therapeutics in Q1 2019 and has held it in 17 quarters since.
Bank of Montreal's DiaMedica Therapeutics position peaked at $982K in Q1 2021.
70 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on Bank of Montreal's 13F filing for Q2 2026, filed 12 Aug 2026.